Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10132016 | 0.85 | DPP4 (0.44) | DPP4SMN1; SMN2L3MBTL1MAPTRAB9A | |
| SCHEMBL10132043 | 0.85 | AGBL2 (0.50) | DPP4SMN1; SMN2L3MBTL1MAPTMAOB | |
| SCHEMBL27462821 | 0.84 | DPP4 (0.43) | DPP4SMN1; SMN2MAOBALDH1A1KDM4E | |
| SCHEMBL15897838 | 0.82 | DPP4 (0.42) | DPP4SMN1; SMN2L3MBTL1HSD17B10MAOB | |
| SCHEMBL16050342 | 0.82 | SMN1; SMN2 (0.48) | DPP4SMN1; SMN2L3MBTL1MAPTRAB9A | |
| SCHEMBL10514399 | 0.81 | HSP90AA1 (0.44) | DPP4SMN1; SMN2HSD17B10RAB9AALDH1A1 | |
| SCHEMBL10515506 | 0.81 | DPP4 (0.41) | DPP4SMN1; SMN2L3MBTL1MAPTRAB9A | |
| SCHEMBL9753881 | 0.78 | MAPT (0.40) | DPP4SMN1; SMN2L3MBTL1MAPTRAB9A | |
| SCHEMBL30349490 | 0.78 | AGBL2 (0.51) | S1PR1S1PR3L3MBTL1AGBL2 | |
| SCHEMBL4528011 | 0.78 | AGBL2 (0.51) | S1PR1S1PR3L3MBTL1AGBL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258136-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-04 | — | — | US | disclosed |
| US-8258136-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-04-05 | — | — | US | disclosed |
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-04-05 | — | — | US | disclosed |
| EP-1958946-B1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20090275589-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-05 | — | — | US | disclosed |
| CN-101326176-A | Pyridazine compound and use thereof | SUMITOMO CHEMICAL CO (JP) | 2008-12-17 | — | — | CN | disclosed |
| EP-1958946-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | PLPBP, PNPO, PDXK | S1PR1 1337/4885S1PR3 1731/4885DPP4 1169/4885 |
| US-20090275589-A1 | Pyridazine Compound and Use Thereof | PLPBP, PNPO, PDXK | S1PR1 1337/4885S1PR3 1731/4885DPP4 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.